ResearchMoz

NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool

GBI Research
Published Date » 2014-03-07
No. Of Pages » 109
   
 GBI Research, the leading business intelligence provider, has released its latest research: ‘NSCLC Therapeutics in APAC Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool’, which provides in-depth insights into the Non-Small Cell Lung Cancer (NSCLC) indication. The report provides an estimation of the market size for 2012 along with market forecasts until 2019 for the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, clinical trial analysis (including failure rates), pipeline analysis, and analysis of deals relevant to NSCLC. The NSCLC market in the APAC region is estimated to have been worth $1.8...
Table of Contents

1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 10
2.1 Symptoms 10
2.2 Etiology 11
2.3 Pathophysiology 12
2.4 Co-morbidities and Complications 12
2.5 Diagnosis 13
2.5.1 Physical Examination 13
2.5.2 Sputum Cytology 13
2.5.3 Imaging Tests 13
2.5.4 Biopsy 14
2.6 Classification 15
2.6.1 Adenocarcinoma 15
2.6.2 Squamous Cell Carcinoma 15
2.6.3 Large Cell Carcinoma 15
2.7 Epidemiology 15
2.8 Prognosis and Disease Staging 16
2.8.1 Staging 16
2.9 Treatment Options 18
2.9.1 Surgery and Radiation Therapy 18
2.9.2 Pharmacological 18
2.9.3 Treatment Algorithms and Prescribing Habits 20

3 Marketed Products 23
3.1 Therapeutic Landscape 24
3.1.1 Alimta (pemetrexed disodium) – Eli Lilly and Company 24
3.1.2 Abraxane (nab-paclitaxel) – Celgene 26
3.1.3 Iressa (gefitinib) – AstraZeneca 28
3.1.4 Tarceva (erlotinib hydrochloride) – F. Hoffmann-La Roche 29
3.1.5 Xalkori (crizotinib) – Pfizer 31
3.1.6 Avastin (bevacizumab) – F. Hoffmann-La Roche 32
3.1.7 Gilotrif (afatinib) – Boehringer Ingelheim 34
3.2 Comparative Efficacy and Safety 34

4 Pipeline Products 37
4.1 Overall Pipeline 37
4.2 Pipeline Analysis by Molecule Type 39
4.3 Pipeline Analysis by Mechanism of Action 41
4.4 Clinical Trials 44
4.4.1 Failure Rate 44
4.4.2 Patient Enrollment and Clinical Trial Size 46
4.4.3 Duration 48
4.5 Promising Drug Candidates in the Pipeline 50
4.5.1 Ramucirumab (IMC-1121B) – Eli Lilly and Company 50
4.5.2 Necitumumab (IMC-11F8) – Eli Lilly and Company 50
4.5.3 Onartuzumab (MetMab) – F. Hoffmann-La Roche 51
4.5.4 Ganetespib (STA-9090) – Synta 52
4.5.5 Nintedanib (BIBF1120) – Boehringer Ingelheim 52
4.5.6 Dacomitinib (PF-00299804) – Pfizer 53
4.5.7 LDK378 – Novartis 54
4.5.8 Yervoy (ipilimumab) – Bristol-Myers Squibb 54
4.5.9 Nivolumab (BMS-936558/ONO-4538) – Bristol Myers Squibb 55

5 Market Forecast to 2019 56
5.1 Geographical Markets 56
5.1.1 APAC Market 56
5.1.2 India 57
5.1.3 Australia 60
5.1.4 China 62
5.1.5 Japan 64
5.2 Drivers and Barriers for the Disease Market 66
5.2.1 Drivers 66
5.2.2 Barriers 66

6 Deals and Strategic Consolidations 68
6.1 Major Co-development Deals 69
6.1.1 OxOnc Enters Co-development Agreement with Pfizer for Crizotinib 70
6.1.2 SFJ Pharma Enters Co-development Agreement with Pfizer for Dacomitinib 70
6.1.3 Merck Enters Co-development Agreement with Endocyte for Cancer Drug 71
6.1.4 Roche Enters Co-development Agreement with Clovis 71
6.1.5 Abbott Laboratories Enters Co-development Agreement with GlaxoSmithKline 71
6.2 Major Licensing Deals 71
6.2.1 Chugai Enters Licensing Agreement with Roche for Onartuzumab and Lebrikizumab 72
6.2.2 Azaya Enters Licensing Agreement with CANbridge Life Sciences for ATI-1123 73
6.2.3 Merck Expands Licensing Agreement with Biomira 73
6.2.4 Clovis Enters Licensing Agreement with Avila Therapeutics 73

7 Appendix 74
7.1 All Pipeline Drugs by Phase 74
7.1.1 Discovery 74
7.1.2 Preclinical 75
7.1.3 IND-filed 78
7.1.4 Phase I 78
7.1.5 Phase II 82
7.1.6 Phase III 86
7.1.7 Undisclosed 89
7.2 Market Forecasts to 2019 97
7.2.1 APAC 97
7.2.2 India 98
7.2.3 Australia 98
7.2.4 China 98
7.2.5 Japan 99
7.3 Market Definitions 99
7.4 Abbreviations 99
7.5 Bibliography 102
7.6 Research Methodology 105
7.6.1 Coverage 105
7.6.2 Secondary Research 106
7.6.3 Primary Research 106
7.6.4 Therapeutic Landscape 106
7.6.5 Geographical Landscape 108
7.6.6 Pipeline Analysis 109
7.7 Expert Panel Validation 109
7.8 Contact Us 109
7.9 Disclaimer 109

List of Tables

Table 1: Non-Small Cell Lung Cancer Market, Common Symptoms of Non-Small Cell Lung Cancer 11
Table 2: Non-Small Cell Lung Cancer Market, Risk Factors of Non-Small Cell Lung Cancer Market 12
Table 3: Non-Small Cell Lung Cancer Market, American Joint Committee on Cancer’s Tumor Node Metastasis Staging System, 2010 17
Table 4: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Discovery), 2013 74
Table 5: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Preclinical), 2013 75
Table 6: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (IND-filed), 2013 78
Table 7: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Phase I), 2013 78
Table 8: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Phase II), 2013 82
Table 9: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Phase III), 2013 86
Table 10: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Undisclosed), 2013 89
Table 11: Non-Small Cell Lung Cancer Market, Asia-Pacific, Market Forecast, 2012–2019 97
Table 12: Non-Small Cell Lung Cancer Market, India, Market Forecast, 2012–2019 98
Table 13: Non-Small Cell Lung Cancer Market, Australia, Market Forecast, 2012–2019 98
Table 14: Non-Small Cell Lung Cancer Market, China, Market Forecast, 2012–2019 98
Table 15: Non-Small Cell Lung Cancer Market, Japan, Market Forecast, 2012–2019 99

List of Figures

Figure 1: Non-Small Cell Lung Cancer Market, Asia-Pacific, Distribution of Prevalence Population, 2012–2019 16
Figure 2: Non-Small Cell Lung Cancer Market, Treatment Algorithm for Early and Advanced Localized Tumors Stages IIIA and IIIB, 2013 20
Figure 3: Non-Small Cell Lung Cancer Market, Treatment Algorithm for Early and Advanced Localized Tumors Stages IIIA and IIIB, 2013 21
Figure 4: Non-Small Cell Lung Cancer Market, Treatment Algorithm for Advanced Metastatic Tumors, 2013 22
Figure 5: Non-Small Cell Lung Cancer Market, Global, Annual Sales, 2012 24
Figure 6: Non-Small Cell Lung Cancer Market, Global, Alimta (pemetrexed disodium) Annual Sales ($bn), 2004–2012 25
Figure 7: Non-Small Cell Lung Cancer Market, Global, Abraxane (nab-paclitaxel) Annual Sales ($m), 2009–2012 27
Figure 8: Non-Small Cell Lung Cancer Market, Global, Iressa (gefitinib) Annual Sales ($m), 2005–2012 28
Figure 9: Non-Small Cell Lung Cancer Market, Global, Tarceva (erlotinib) Annual Sales ($bn), 2006–2012 30
Figure 10: Non-Small Cell Lung Cancer Market, Global, Xalkori (crizotinib) Annual Sales ($m), 2012–2013 31
Figure 11: Non-Small Cell Lung Cancer Market, Global, Avastin (bevacizumab) Annual Sales ($bn), 2006–2012 33
Figure 12: Non-Small Cell Lung Cancer Market, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013 35
Figure 13: Non-Small Cell Lung Cancer Market, Global, Pipeline by Stage of Development, Program Type and Route of Administration, 2013 38
Figure 14: Non-Small Cell Lung Cancer Market, Global, Pipeline by Molecule Type and Stage of Development, 2013 40
Figure 15: Non-Small Cell Lung Cancer Market, Global, Pipeline by Mechanism of Action, 2013 42
Figure 16: Non-Small Cell Lung Cancer Market, Global, Pipeline by Mechanism of Action, Molecule Type and Stage of Development (Number), 2013 43
Figure 17: Non-Small Cell Lung Cancer Market, Global, Clinical Trial Failure Rate (%), 2013 45
Figure 18: Non-Small Cell Lung Cancer Market, Global, Clinical Trial Size (Participants), 2013 47
Figure 19: Non-Small Cell Lung Cancer Market, Global, Pipeline Clinical Trial Duration (months), 2013 49
Figure 20: Non-Small Cell Lung Cancer Market, Asia-Pacific, Market Size, 2012–2019 57
Figure 21: Non-Small Cell Lung Cancer Market, India, Market Size, 2012–2019 59
Figure 22: Non-Small Cell Lung Cancer Market, Australia, Market Size, 2012–2019 61
Figure 23: Non-Small Cell Lung Cancer Market, China, Market Size, 2012–2019 63
Figure 24: Non-Small Cell Lung Cancer Market, Japan, Market Size, 2012–2019 65
Figure 25: Non-Small Cell Lung Cancer Market, Global Deals by Value, Year and Stage of Development, 2006–2013 68
Figure 26: Non-Small Cell Lung Cancer Market, Global, Deals by Phase, Molecule Type and Mechanism of Action, 2006–2013 69
Figure 27: Non-Small Cell Lung Cancer Market, Global, Co-development Deals by Geography, 2006–2013 70
Figure 28: Non-Small Cell Lung Cancer Market, Global, Licensing Deals by Geography, 2006–2013 72
Figure 29: GBI Research Market Forecasting Model (Example) 108

Upcoming Reports:

Platinum Group Metals Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Platinum group metals (PGMs) is a family of metals which includes platinum, rhodium, osmium, ruthenium, palladium and iridium. Properties such as high melting point make them high temperature resistant and corrosion resistant. End use industrial applications of platinum group metals include their use in the catalysis of petroleum processing, production of nitric acid, flat panel monitors, manufacturing of medical tools such as pacemakers and stain for DNA fingerprints, automobiles, glass fiber, hard drives, nylon razors and others. Platinum metals posses’ high aesthetic features...
Railroad Equipment Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Companies in railroad equipment manufacturing industry manufacture freight and passenger rail cars, locomotives, brakes and other parts and equipment used in railroad operations. The transportation equipments manufacturing industry has become central to economical development. Demand for these equipments has risen sharply as the volume of transported goods and the distance covered have expanded. This trend is expected to continue over coming years. The demand for freight rolling stock is being driven by hike in fuel prices globally as higher prices have shifted freight transport...
Poland: market of machinery for cleaning, sorting or grading seeds and grains
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the machinery for cleaning, sorting or grading seeds and grains market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the machinery for cleaning, sorting or grading seeds and grains market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

A Health Tech Incubator Started by GE Healthcare
Oct 30, 2014  
For the very first time, a health tech start up campus has been established by GE Healthcare at its headquarters at Helsinki, Finland. This area already has about twenty such healthcare start ups that are working on cloud services, wireless technologies, apps, and sensors that aim at improving healthcare. The main rationale behind such a step is providing opportunities for further...
Net Earnings of DuPont Increases 52% despite Agricultural Turmoil
Oct 29, 2014  
DuPont - The Wilmington, Del-based leading chemical company faced decline of three percent sales to $7.5 billion in the quarter ending of September 30. The company’s third-quarter earnings were increased by 52 percent to $433 million albeit the slow global growth and agricultural downside.   The company witnessed the biggest drags from chemical sales with eight percent...
Appeal for Sanitization in Construction Industry through Government Regulations: CIOB Ghana
Oct 29, 2014  
Rockson Dogbegah - The Chairman of the Chartered Institute of Building Ghana commented that the construction industry needs a thorough cleaning up and assurance of proper growth. Mr. Dogbegah also said that a few factors are extremely important for a proper development in the construction industry. These include keen adherence to standards, supreme sense of professionalism, and sheer pursuance...
Facebook Hints of Rise in Expenses in 2015, Shares Drop
Oct 29, 2014  
Facebook has announced on Tuesday that it is prepping for a dramatic rise in spending in the year 2015. This warning has come combined with a projected slowdown in the company’s revenues after revenues were analyzed at the end of the third quarter of the year. The plans of such hefty spending in the next financial year by the company are indicative of stress in the investor...
Samsung Records Poorest Profits in Q3 2014
Oct 29, 2014  
In the quarter ending September 2014, Samsung Electronics Co. Ltd registered the smallest earnings ever in two years. The drop in earnings can be easily attributed to heavy competition from new Chinese devices and the Apple phones. The net income stood at US$4 billion for the South Korea-based company. Apple has been Samsung’s strongest contender ever since the latter entered the...